The decision to implement digital pathology is easier than the implementation itself. Labs that approach the transition without a structured plan often find themselves managing dual workflows longer than expected, dealing with staff resistance that could have been anticipated, or discovering infrastructure gaps after contracts are signed.
This guide covers the full implementation journey: from initial assessment through daily clinical use. It draws on what labs that have successfully made the transition have learned, and what Lumea has observed across hundreds of deployments. No two implementations are identical, but the same planning principles apply regardless of lab size, specialty, or starting point.
How long does digital pathology implementation take? A typical deployment, including software setup, LIS integration, staff training, and FDA validation for primary diagnosis, runs between three and nine months from contract to go-live. Labs that start with a focused scope, such as a single specimen type or a single site, can move faster. The sections below explain why.
Phase 1: Assess and Plan
Evaluate Your Current Workflow
Before evaluating vendors or technology, understand where your current workflow has the most friction. The most common pain points that drive labs toward digital pathology are: consultation delays caused by geographic distance, slow turnaround times on ancillary and molecular test ordering, inefficient slide routing and sorting, difficulty covering multiple sites with existing pathologist capacity, and the administrative burden of physical slide management and storage.
Identifying your specific pain points shapes everything that follows, including which technology components you prioritize, which vendor capabilities matter most, and how you’ll measure success after go-live.
Define Your Objectives
Vague goals produce vague outcomes. Before engaging vendors, define what success looks like in concrete terms. Examples of well-defined objectives include reducing average case turnaround time by 30%, enabling primary diagnosis from two remote sites, integrating molecular test ordering into the pathologist’s diagnostic workflow, or achieving 100% digital primary diagnosis for prostate core biopsies within 12 months.
Quantified objectives help you evaluate vendor proposals objectively, build the ROI case for leadership and finance, and measure actual outcomes after implementation.
Assess Your Resources
Going digital is an investment in money, time, and people. Before planning a timeline, honestly evaluate:
Budget: Account for hardware (scanners, if not already in place), software licensing, IT infrastructure upgrades, training, validation, and ongoing maintenance. Include a contingency for the reduced productivity that accompanies any major workflow change during the transition period.
Staffing: Identify who will lead the implementation internally. This person needs the authority to make workflow decisions, the time to manage vendor relationships, and the credibility to drive adoption among lab staff and pathologists. Implementations without a clear internal champion consistently struggle.
Timeline: Balance speed of execution against operational disruption. A phased rollout that starts with a single specimen type or a single site is slower to full deployment but significantly lower risk than a simultaneous full-lab transition.
Engage Stakeholders Early
The most common reason digital pathology implementations stall is not technology — it’s people. Pathologists who weren’t involved in the selection process feel imposed upon. Lab staff who weren’t consulted on workflow changes resist adoption. IT teams who were brought in late discover infrastructure gaps that delay go-live.
Involve pathologists, lab personnel, IT staff, administrators, and finance from the beginning. Their input improves the implementation plan and their early involvement creates the sense of ownership that drives adoption. When communicating the rationale for the change, explain the why clearly rather than simply announcing imminent changes. People adopt new workflows more readily when they understand what problem the change is solving.
Change Management Is Not Optional
Of all the factors that determine whether a digital pathology implementation succeeds or stalls, change management is the most consistently underestimated. Dr. Syed Hoda, Director of Digital Pathology at NYU Langone and the pathologist who led NYU’s full clinical digital transformation, learned this firsthand. His institution brought in a dedicated change management expert who helped organize town halls, small group sessions, polling, and a full retreat day before a single scanner went live — all designed to let pathologists voice concerns before go-live rather than after.
“There’s a lot of resistance built into pathologists,” Dr. Hoda shared on his episode of the PathPulse podcast. “There’s change management involved, which, if you’re in a company, you understand what that means. There’s a huge amount of change management here, and telling doctors what to do and how to do their work is like one of the great challenges of healthcare.”
His change management expert reframed what a difficult meeting actually meant: “People were complaining, and you want that. You want to hear what people are complaining about. If you just go through the silent world of thinking ‘I’m the leader and I’ll make this happen,’ what’s going to happen is it’s going to go live and then they’re going to complain about it. And then you never address their complaints.”
The cost of skipping this step is real. Dr. Hoda recounted speaking with a private lab that set a hard deadline for going fully digital without adequate change management preparation. Nearly half their pathologists left before the deadline. In a specialty already facing workforce shortages, that outcome is not recoverable.
The practical implication for labs planning an implementation: budget time and resources for change management the same way you budget for hardware and software. Invite outside speakers. Hold information sessions before any purchase decisions are made. Create structured channels for staff to voice concerns. The goal is to make the transition feel predictable rather than imposed — and the difference between those two experiences determines whether your pathologists adopt the system or resist it.
Phase 2: Select Technology
Key Components to Evaluate
A complete digital pathology implementation involves several technology components that need to work together:
Whole Slide Image (WSI) Scanner: The scanner converts glass slides into digital images. Key evaluation criteria are throughput (slides per hour), image quality, reliability, scanner footprint, and format compatibility with your chosen software. Ensure you have a redundancy plan — a single scanner failure in a fully digital workflow is a significant disruption.
Image Management System (IMS) and Viewer: This is where pathologists do their diagnostic work. Evaluate rendering speed (lag kills adoption), workflow customization, AI integration capabilities, mobile and remote access, and LIS integration depth. Ask for a live demonstration on your own cases, not a vendor-controlled demo with optimized slides.
LIS Integration: How deeply the digital pathology platform integrates with your Laboratory Information System is one of the most important and most underestimated factors in a successful implementation. A shallow integration, where the viewer is essentially a link that opens a separate application, creates a parallel workflow that adds friction rather than removing it. A deep bidirectional integration means case management, image routing, AI results, molecular test ordering, and reporting all happen in one workspace.
Pre-Analytical Tissue-Handling Technology: Digital pathology’s benefits are limited by the quality of the specimen that reaches the scanner. Tissue-handling devices that standardize collection, reduce fragmentation, and preserve anatomic orientation improve the downstream diagnostic value of every scan. These tools are often overlooked in implementation planning but consistently rank among the highest-ROI components for labs that adopt them.
AI Tools: Most modern digital pathology platforms support third-party AI integration. Evaluate whether the platform you’re considering has an open ecosystem that lets you choose the best AI for each application, or whether it locks you into proprietary AI that may not serve all your specialty needs.
Evaluate Vendors Carefully
Request demonstrations of actual, production-ready products — not videos of idealized scenarios or software still in development. Ask to speak with reference labs that have completed implementation, specifically users at the bench and diagnostic level rather than only administrators or executives. Visiting a live lab using the system you’re considering is invaluable.
Check FDA clearance status for any components used for primary diagnosis. Lumea’s Viewer+ holds FDA 510(k) clearance for primary clinical diagnosis and CE marking under IVDR for clinical use in Europe.
Ask vendors explicitly about implementation support: who manages the process, what the typical timeline is, and what happens when things don’t go according to plan. A vendor’s implementation track record matters as much as their product features.
Budget Realistically
Build your budget around five cost categories:
- Hardware: Scanner(s), server infrastructure (if on-premise storage), workstations, monitors
- Software: IMS/viewer licensing, LIS integration fees, AI tool subscriptions
- Implementation: Vendor professional services, IT staff time, workflow design consulting
- Validation: Staff time for FDA validation, quality assurance testing
- Ongoing: Storage costs, software maintenance, support contracts, training for new staff
Expect reduced productivity during the transition period. Build that cost into your ROI model rather than treating go-live as the moment benefits begin. Most labs see productivity return to baseline within 60-90 days of go-live and begin exceeding baseline productivity within six months.
Phase 3: Prepare for Implementation
Infrastructure Readiness
Digital pathology is infrastructure-intensive. Address these requirements before any software is installed:
Network bandwidth: Whole slide images are 1-2GB files. Rendering them at diagnostic quality requires sufficient bandwidth between your scanner, storage, and viewer workstations. Inadequate network infrastructure is one of the most common causes of poor adoption — pathologists who experience loading delays revert to glass.
Storage capacity: Plan for 1-2GB per case at 20x magnification as a baseline estimate. Model your storage needs over a 3-5 year horizon, not just year one. Determine your cloud vs. on-premise strategy and ensure your chosen approach is HIPAA compliant before storing any patient data.
Physical space: A WSI scanner requires a stable surface free from vibration, adequate power, and ideally battery backup to prevent scan interruption during power fluctuations. These are physical requirements that labs sometimes overlook until installation day.
IT security: Ensure role-based access controls, encrypted data transmission, and a documented disaster recovery plan are in place before go-live. These are HIPAA requirements, not optional.
Workflow Mapping
Map your current workflow in detail, then design the digital workflow alongside it. Identify every step where the process changes and document the new standard operating procedure for each. The places where digital pathology creates new steps, such as scanning, QC review of scanned images, and data migration, need to be staffed and timed. Don’t assume the scanner runs itself.
Develop contingency procedures for the inevitable moments when technology fails: what happens if the scanner goes down, if the network is slow, or if the software is unavailable? Labs that pre-plan for downtime handle it with minimal disruption. Labs that don’t plan for it face significant stress and patient care delays.
Staff Training
Train every user type, including lab technicians, pathologists, administrative staff, and IT support, before go-live. Don’t limit training to a single session — plan for initial training, a follow-up session after the first week of use, and ongoing access to support resources.
For pathologists specifically, the validation phase described below will provide substantial hands-on experience with the system before they’re using it for primary diagnosis. Take advantage of this period to identify individual learning curves and address concerns before they become resistance.
NYU Langone’s implementation deliberately sequenced capability adoption — proficiency in daily digital workflow before AI, AI before remote sign-out. Defining clear competency milestones before introducing new capabilities reduces cognitive overload and builds pathologist confidence progressively.
Phase 4: Validate and Pilot
FDA Validation for Primary Diagnosis
Any lab using digital pathology for primary clinical diagnosis is required to validate their workflow before doing so. FDA guidance requires demonstrating that diagnostic concordance between digital and glass slide diagnosis meets an acceptable threshold, typically through a defined number of comparison cases reviewed by the pathologists who will use the system.
Validation takes time, but it’s a one-time investment that protects your lab legally and gives your pathologists genuine confidence in the system. Lumea’s implementation team has developed streamlined validation protocols based on deployments across hundreds of labs and can guide you through the process efficiently.
Pilot Program
Before full deployment, run a controlled pilot with a limited scope: one specimen type, one pathologist or group, one clinical partner. The goal is to identify workflow gaps, technology issues, and adoption barriers in a controlled environment before they affect your broader operation.
Engage a clinical partner who is willing to participate in the process openly, including providing honest feedback when things aren’t working. The best pilot feedback comes from users who feel safe saying what’s wrong, not just what’s right.
Gather structured feedback after the pilot, make documented adjustments, and communicate those adjustments to participants. Seeing their feedback acted on builds the trust that drives broader adoption.
Phase 5: Full Implementation and Go-Live
Phased Rollout
Implement in stages rather than switching the entire lab simultaneously. A typical sequence is: begin with a single specimen type (prostate biopsies are a common starting point given Lumea’s specialization), expand to additional specimen types, add pathologists and sites, and finally move to 100% digital primary diagnosis across all workflows.
The phased approach manages risk, allows the team to build confidence progressively, and enables you to demonstrate ROI to leadership at each stage rather than waiting for full deployment.
Data Migration
If you’re transitioning from an existing digital system or migrating historical data, plan the migration carefully. Verify data integrity after migration before decommissioning the old system. Ensure all migrated cases are accessible and correctly associated with patient records in the new system. A limited rollout approach during migration reduces the risk of data issues affecting patient care.
Ongoing Communication
Maintain structured communication with all stakeholders throughout go-live and the weeks following. Weekly check-ins with the implementation champion, a clear channel for users to report issues, and visible responsiveness to problems reported all sustain the momentum that early adoption requires.
Phase 6: Daily Practice and Continuous Improvement
Monitor and Measure
After go-live, track the metrics you defined in Phase 1. Are turnaround times improving? Is pathologist productivity recovering toward baseline? Are consultation times shorter? Are molecular test orders being completed appropriately?
Regular monitoring lets you identify problems early, demonstrate ROI to leadership, and make the data-driven case for additional investment in the platform over time.
Stay Current
Digital pathology is evolving rapidly. New AI tools, new scanner capabilities, and new regulatory guidance emerge regularly. Labs that stay connected through conferences, professional organizations, and vendor updates maintain the competitive advantage that drove the initial investment. Lumea’s annual Digital Diagnostic Summit is specifically designed for labs that want to stay at the forefront of what’s possible in digital pathology.
The benefits of going fully digital extend beyond operational efficiency. Dr. Hoda described a transformation in how pathology is perceived at NYU Langone — more medical students, equal standing with radiology at tumor boards, and a specialty that no longer carries the perception of being slow to modernize. ‘It takes the lid off the potential cap that was kind of there,’ he said. ‘Adopting a digital workflow means that we’re comfortable with moving into the future.’
Continuous Improvement
The implementation is complete, but the optimization isn’t. Solicit ongoing feedback from pathologists and lab staff. Review workflows periodically for new automation opportunities. Evaluate new AI integrations as they become available. The labs that see the greatest long-term return from digital pathology treat it as a continuously improving platform rather than a one-time installation.
Ready to Start?
The implementation journey is significant, but it’s navigable — and the labs that have completed it consistently describe it as one of the most impactful operational decisions they’ve made.
Lumea’s consulting services team has guided hundreds of labs through every phase of the process described above, from initial workflow assessment through go-live and beyond. If you’re evaluating digital pathology or planning an implementation, we’re happy to walk through your specific situation.
Request a consultation to get started today.
For more resources on the digital pathology transition, explore Lumea’s customer success stories and the Digital Diagnostic Digest, our quarterly publication covering real-world digital pathology implementation.
